Probably not. This is the third trial across as many companies to fail. At $50-100 million to do them, it’s unlikely anyone will try another one for a long time.
It’s not about the formulation, CBD just doesn’t have enough activity in the target disease state to prove it does anything. If you can’t separate from placebo, you don’t have a product.